Gitnux/Report 2026

Second Heart Attack Statistics

Even after discharge, recurrence is not a rare event with 22% of patients with established coronary heart disease facing a recurrent major cardiovascular event, so Second Heart Attack pulls together the latest outcomes and prevention evidence that targets that risk. You will see how therapies and follow up can shift the odds, from 7.0% and 12.3% 1 year mortality after STEMI versus NSTEMI to benefits like a 20% lower risk with sacubitril/valsartan, 15% with evolocumab and alirocumab, 25% with icosapent ethyl, and how cardiac rehab and adherence gaps matter.
32Statistics
32Sources
4Sections
7mRead
2 mo agoUpdated
Second Heart Attack Statistics
James OkoroWritten by James Okoro·Edited by Margot Villeneuve·Fact-checked by Jonathan Hale
Last verified May 13, 2026
Verified via a 4-step process
01Source

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Verify

Each statistic is independently verified via reproduction analysis and cross-referencing against independent databases.

03Grade

Figures are graded by cross-model consensus. Statistics failing independent corroboration are excluded regardless of how widely cited.

04Cite

Every figure carries a primary source. We maintain stable URLs and versioned verification dates so the report can be cited.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Next review Nov 2026
After a first heart attack, the risk does not reset and in the UK alone 204,000 people were discharged following heart attack in 2019 to 2020, setting the scale for how many can still go on to experience a second. Across major studies, recurrence benchmarks range from 22% having a recurrent major cardiovascular event in patients with established coronary heart disease to targeted therapies that cut cardiovascular death, hospitalization, or stent related events by double digit percentages. Let’s look at how these risk swings are measured and what they mean for preventing a true second heart attack.

Key Takeaways

  • In the UK, 204,000 people were discharged from hospital following heart attack in 2019–20 (annual case volume used to contextualize recurrence).
  • In a large cohort study of patients with established coronary heart disease, 22% experienced a recurrent major cardiovascular event over follow-up (recurrence benchmark relevant to “second” events).
  • In the ACTION Registry-GWTG, 1-year mortality after myocardial infarction was 7.0% for ST-elevation MI and 12.3% for non–ST-elevation MI (outcome base for secondary prevention impact).
  • After myocardial infarction, adherence to statins is strongly associated with reduced risk of recurrent major cardiovascular events (reported hazard reductions in observational analyses vary by study but typically show significant risk decreases).
  • A Cochrane review found that cardiac rehabilitation reduces mortality after myocardial infarction (with quantified effect sizes reported across included trials).
  • The global digital therapeutics market reached about $5B in 2023 and is projected to grow (category includes interventions targeting chronic disease and adherence).
  • The global remote patient monitoring market size was about $2–3B in 2023 with rapid projected growth (secondary prevention monitoring for cardiometabolic risk).
  • The U.S. home health care market revenue was about $100B+ in 2023 (relevant for post-discharge secondary prevention services).
  • The U.S. AHA reports that the number of stroke and heart disease deaths remains high, motivating increased adoption of secondary prevention programs (public health trend quantified in annual death counts).
  • The Global Burden of Disease 2021 study reported that ischemic heart disease remains the leading cause of death worldwide (quantified burden in deaths and DALYs).
  • In the U.S., cardiac rehabilitation participation after MI is often reported around 20%–30% in published studies (quantified participation gap).

Most second heart attacks can be prevented through guideline treatments and statin plus newer add ons, supported by trials.

Related reading

01 · Category

Prevalence & Risk2 stats

01
In the UK, 204,000 people were discharged from hospital following heart attack in 2019–20 (annual case volume used to contextualize recurrence).
02
In a large cohort study of patients with established coronary heart disease, 22% experienced a recurrent major cardiovascular event over follow-up (recurrence benchmark relevant to “second” events).
Interpretation

Prevalence & Risk Interpretation

From the prevalence and risk angle, the data suggest that a substantial share of people is vulnerable to a second event, with 204,000 UK patients discharged after a heart attack in 2019 to 2020 and 22% of those with established coronary heart disease experiencing a recurrent major cardiovascular event during follow-up.

02 · Category

Prevention & Outcomes15 stats

01
In the ACTION Registry-GWTG, 1-year mortality after myocardial infarction was 7.0% for ST-elevation MI and 12.3% for non–ST-elevation MI (outcome base for secondary prevention impact).
02
After myocardial infarction, adherence to statins is strongly associated with reduced risk of recurrent major cardiovascular events (reported hazard reductions in observational analyses vary by study but typically show significant risk decreases).
03
A Cochrane review found that cardiac rehabilitation reduces mortality after myocardial infarction (with quantified effect sizes reported across included trials).
04
Guideline-based secondary prevention use of antiplatelet therapy, statins, and beta-blockers reduces recurrent events in randomized trials; IMPROVE-IT reported incremental benefit when adding ezetimibe to statin therapy with a quantified reduction in cardiovascular events.
05
In PARADIGM-HF, sacubitril/valsartan reduced the risk of cardiovascular death or hospitalization for heart failure by 20% versus enalapril (19% relative risk reduction).
06
In the DAPT study, extended dual antiplatelet therapy reduced stent thrombosis and major adverse cardiovascular events but increased bleeding; recurrence/end-point quantification is reported.
07
In the CREDO-Kyoto registry, the hazard of recurrent events after percutaneous coronary intervention was reduced with more intensive lipid lowering, supporting recurrence risk reduction with quantified event-rate differences in subgroups.
08
The FDA-approved PCSK9 inhibitor evolocumab (FOURIER) reduced the risk of major cardiovascular events by 15% vs placebo in a randomized trial.
09
The FDA-approved PCSK9 inhibitor alirocumab (ODYSSEY OUTCOMES) reduced the risk of major adverse cardiovascular events by 15% vs placebo after acute coronary syndrome with quantified relative risk reduction.
10
In EMPA-REG OUTCOME, empagliflozin reduced cardiovascular death by 38% vs placebo among patients with type 2 diabetes and established cardiovascular disease.
11
In CANVAS, canagliflozin reduced the risk of the composite of CV death, nonfatal MI, or nonfatal stroke by 14% vs placebo.
12
In the REDUCE-IT trial, icosapent ethyl reduced the risk of major adverse cardiovascular events by 25% vs placebo among statin-treated patients with elevated triglycerides.
13
In the STABILITY trial, ticagrelor vs placebo reduced the rate of cardiovascular death, MI, or stroke by 10% (quantified relative risk reduction reported).
14
In the ASCEND trial, aspirin reduced serious vascular events but increased major bleeding; quantification of event rates supports balancing prevention benefits and harms.
15
In the INTERHEART case-control analysis, dyslipidemia, smoking, hypertension, and diabetes accounted for a large proportion of risk in acute myocardial infarction (quantified population-attributable fractions reported).
Interpretation

Prevention & Outcomes Interpretation

Overall, the prevention focus is supported by trial and real-world evidence showing consistent reductions in recurrent risk, such as a 15% drop in major cardiovascular events with PCSK9 inhibitors and up to a 38% lower cardiovascular death with empagliflozin, alongside better outcomes like 7.0% versus 12.3% 1-year mortality after STEMI versus NSTEMI in ACTION, reinforcing that timely secondary prevention meaningfully improves outcomes after a second heart attack is at stake.

More related reading

03 · Category

Market Size7 stats

01
The global digital therapeutics market reached about $5B in 2023 and is projected to grow (category includes interventions targeting chronic disease and adherence).
02
The global remote patient monitoring market size was about $2–3B in 2023 with rapid projected growth (secondary prevention monitoring for cardiometabolic risk).
03
The U.S. home health care market revenue was about $100B+ in 2023 (relevant for post-discharge secondary prevention services).
04
The global anticoagulants market was valued at roughly $40B+ in 2023 (medication class relevant to recurrent event prevention in selected patients).
05
The global statins market was valued at about $20B+ in 2023 (core of secondary prevention).
06
The global PCSK9 inhibitors market was valued at around $5B in 2023 (expanding secondary prevention uptake).
07
The global heart valve replacement market exceeded $10B in 2023 (related cardiology care and comorbidity burden after MI/secondary events).
Interpretation

Market Size Interpretation

In 2023, the market opportunity for Second Heart Attack prevention is already substantial, with global digital therapeutics at about $5B and remote patient monitoring at roughly $2 to $3B, while adjacent secondary prevention sectors are much larger such as anticoagulants at $40B+ and statins at $20B+ and are continuing to expand.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
James Okoro. (2026, February 13). Second Heart Attack Statistics. Gitnux. https://gitnux.org/second-heart-attack-statistics
MLA
James Okoro. "Second Heart Attack Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/second-heart-attack-statistics.
Chicago
James Okoro. 2026. "Second Heart Attack Statistics." Gitnux. https://gitnux.org/second-heart-attack-statistics.

Sources & references

32 datasets cited across this report · attribution is report-level

digital.nhs.uknejm.orgahajournals.orgjamanetwork.comcochranelibrary.comthelancet.comfortunebusinessinsights.comgrandviewresearch.comibisworld.comglobenewswire.comprecedenceresearch.comalliedmarketresearch.comheart.orgvizhub.healthdata.orgncbi.nlm.nih.gov

+17 additional datasets cited (not shown individually)